Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT07221227

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Led by GlaxoSmithKline · Updated on 2026-04-16

1200

Participants Needed

49

Research Sites

320 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

CONDITIONS

Official Title

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able and willing to understand and sign a written informed consent form before study procedures
  • Age between 18 and 75 years at enrollment
  • History or presence of two or more of the five components of metabolic syndrome according to the American Heart Association
  • Liver biopsy confirming MASH with stage F2 or F3 fibrosis and a NAS score of 4 or higher, confirmed by a central pathologist
Not Eligible

You will not qualify if you...

  • Contraindication or inability to undergo percutaneous liver biopsy
  • ALT or AST levels five times or more above the upper limit of normal
  • Total bilirubin level 1.3 mg/dL or higher, except for Gilbert's syndrome cases with isolated bilirubin increase and low direct bilirubin
  • Serum albumin level 3.5 g/dL or lower
  • INR 1.3 or higher not caused by anticoagulation therapy (exceptions possible with medical approval)
  • Alkaline phosphatase level twice or more above the upper limit of normal
  • Platelet count below 140,000/mm3 (counts between 110,000/mm3 and 140,000/mm3 may be considered after medical review)
  • Serum creatinine 1.5 mg/dL or higher or creatinine clearance 60 mL/min/1.73 m2 or lower
  • Alpha-fetoprotein level 20 ng/mL or higher
  • Glycated hemoglobin 9.0% or higher
  • Model for End-Stage Liver Disease score 12 or higher unless due to non-liver causes
  • Phosphatidyl ethanol level 80 ng/mL or higher at screening
  • Infection with HIV, hepatitis B (detectable HBsAg), or hepatitis C
  • Chronic liver diseases other than MASH, including alcoholic liver disease, portal hypertension, viral hepatitis, cirrhosis, or decompensated liver disease
  • Current or history of excessive alcohol use for 3 months or more within the past 12 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 49 locations

1

GSK Investigational Site

Arcadia, California, United States, 91006

Actively Recruiting

2

GSK Investigational Site

Covina, California, United States, 91723

Actively Recruiting

3

GSK Investigational Site

Los Angeles, California, United States, 90057

Actively Recruiting

4

GSK Investigational Site

Santa Maria, California, United States, 93458

Actively Recruiting

5

GSK Investigational Site

Van Nuys, California, United States, 91405

Actively Recruiting

6

GSK Investigational Site

Boynton Beach, Florida, United States, 33435

Actively Recruiting

7

GSK Investigational Site

Cape Coral, Florida, United States, 33914

Actively Recruiting

8

GSK Investigational Site

Hialeah, Florida, United States, 33016

Actively Recruiting

9

GSK Investigational Site

Hialeah, Florida, United States, 33016

Actively Recruiting

10

GSK Investigational Site

Inverness, Florida, United States, 34452

Actively Recruiting

11

GSK Investigational Site

Jacksonville, Florida, United States, 32216

Actively Recruiting

12

GSK Investigational Site

Kissimmee, Florida, United States, 34744

Actively Recruiting

13

GSK Investigational Site

Lakeland, Florida, United States, 33803

Actively Recruiting

14

GSK Investigational Site

Maitland, Florida, United States, 32751

Actively Recruiting

15

GSK Investigational Site

Miami, Florida, United States, 33135

Actively Recruiting

16

GSK Investigational Site

Miami, Florida, United States, 33144

Actively Recruiting

17

GSK Investigational Site

Miami, Florida, United States, 33155

Actively Recruiting

18

GSK Investigational Site

Miami, Florida, United States, 33156

Actively Recruiting

19

GSK Investigational Site

Miami, Florida, United States, 33184

Actively Recruiting

20

GSK Investigational Site

Miami Lakes, Florida, United States, 33014

Actively Recruiting

21

GSK Investigational Site

Ocala, Florida, United States, 34471

Actively Recruiting

22

GSK Investigational Site

Palmetto Bay, Florida, United States, 33157

Actively Recruiting

23

GSK Investigational Site

Topeka, Kansas, United States, 66606

Actively Recruiting

24

GSK Investigational Site

Springfield, Missouri, United States, 62703

Actively Recruiting

25

GSK Investigational Site

St Louis, Missouri, United States, 63141

Actively Recruiting

26

GSK Investigational Site

East Syracuse, New York, United States, 13057

Actively Recruiting

27

GSK Investigational Site

New York, New York, United States, 10036

Actively Recruiting

28

GSK Investigational Site

New York, New York, United States, 10036

Actively Recruiting

29

GSK Investigational Site

Morehead City, North Carolina, United States, 28557

Actively Recruiting

30

GSK Investigational Site

Akron, Ohio, United States, 44320

Actively Recruiting

31

GSK Investigational Site

Springboro, Ohio, United States, 45066

Actively Recruiting

32

GSK Investigational Site

Chattanooga, Tennessee, United States, 37421

Actively Recruiting

33

GSK Investigational Site

Austin, Texas, United States, 78704

Actively Recruiting

34

GSK Investigational Site

Austin, Texas, United States, 78759

Actively Recruiting

35

GSK Investigational Site

Bellaire, Texas, United States, 77401

Actively Recruiting

36

GSK Investigational Site

Brownsville, Texas, United States, 78526

Actively Recruiting

37

GSK Investigational Site

Dallas, Texas, United States, 75243

Actively Recruiting

38

GSK Investigational Site

DeSoto, Texas, United States, 75115

Actively Recruiting

39

GSK Investigational Site

Richmond, Texas, United States, 77406

Actively Recruiting

40

GSK Investigational Site

San Antonio, Texas, United States, 78215

Actively Recruiting

41

GSK Investigational Site

San Antonio, Texas, United States, 78229

Actively Recruiting

42

GSK Investigational Site

Seabrook, Texas, United States, 77586

Actively Recruiting

43

GSK Investigational Site

Sugar Land, Texas, United States, 77479

Actively Recruiting

44

GSK Investigational Site

Tomball, Texas, United States, 77375

Actively Recruiting

45

GSK Investigational Site

Waco, Texas, United States, 76710

Actively Recruiting

46

GSK Investigational Site

Waco, Texas, United States, 76712

Actively Recruiting

47

GSK Investigational Site

West Jordan, Utah, United States, 84088

Actively Recruiting

48

GSK Investigational Site

Manassas, Virginia, United States, 20110

Actively Recruiting

49

GSK Investigational Site

Seattle, Washington, United States, 98105

Actively Recruiting

Loading map...

Research Team

U

US GSK Clinical Trials Call Center

CONTACT

E

EU GSK Clinical Trials Call Center

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH | DecenTrialz